TABLE 2.
CFU recovery in skin homogenates following SF-8300 challenge and treatment with vancomycin, linezolid, MEDI4893*, combination therapy, or R347
| Drug (dose, mg/kg/day)a | MAb (dose, mg/kg/day)a | Log10 CFU/ml ± SEM at postchallenge time (h): |
||
|---|---|---|---|---|
| 24 | 72 | 168 | ||
| Vancomycin (200) | None | 8.44 ± 0.30 | 7.92 ± 0.20b,d | 7.54 ± 0.11b |
| MEDI4893* (2.5) | 8.49 ± 0.06 | 7.63 ± 0.12b,d | 6.18 ± 0.25b,c,d | |
| Linezolid (10) | None | 8.52 ± 0.16 | 8.40 ± 0.07 | 7.21 ± 0.44b |
| MEDI4893* (2.5) | 8.58 ± 0.31 | 8.13 ± 0.10b | 7.23 ± 0.15b | |
| None | MEDI4893* (2.5) | 8.00 ± 0.01 | 8.98 ± 0.15e | 7.66 ± 0.31b |
| R347 (15.0) | 8.52 ± 0.11 | 8.76 ± 0.16 | 8.53 ± 0.19 | |
a
Vancomycin and linezolid were dosed at 3, 8, 24, and 32 h postinfection. MEDI4893* and R347 were dosed at 3 h postinfection. See Materials and Methods for further details.
b
The CFU value is significantly lower than that for the R347 control (P < 0.05).
c
Vancomycin combination therapy is significantly different from vancomycin monotherapy (P < 0.05).
d
Significantly different from MEDI4893* monotherapy (P < 0.05).
e
Significantly different from vancomycin monotherapy and vancomycin-MEDI4893* therapy (P < 0.05).